

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 30, 2010**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Sangamo Biosciences, Inc.

File No. 0-30171 - CF#24824

Sangamo Biosciences, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 5, 2010.

Based on representations by Sangamo Biosciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.8	through February 17, 2020
Exhibit 10.10	through February 17, 2020
Exhibit 10.14	through February 17, 2020
Exhibit 10.17	through February 17, 2020
Exhibit 10.20	through February 17, 2020
Exhibit 10.25	through February 10, 2014
Exhibit 10.32	through June 5, 2018
Exhibit 10.39	through December 31, 2015
Exhibit 10.44	through March 1, 2012

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kathleen Krebs
Special Counsel